The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Regional Suppression of Tumor Growth by In Vivo Transfer of a cDNA Encoding a Secreted Form of the Extracellular Domain of the flt-1 Vascular Endothelial Growth Factor Receptor
Abstract
Vascular endothelial growth factor (VEGF), a potent angiogenic mediator, is overexpressed in most solid tumors. On the basis of the knowledge that solid tumor growth beyond a small volume is critically dependent on angiogenesis, and that adenovirus (Ad) vectors can mediate efficient in vivo gene transfer and expression, we hypothesized that Ad-mediated transfer of a secreted form of the extracellular domain of the flt-1 VEGF receptor (Adsflt) would suppress tumor growth on a regional basis. To evaluate this concept, three tumor models were examined using a murine colon carcinoma cell line and syngeneic BALB/c mice. First, mice with preestablished splenic CT26.CL25 tumors and liver metastases were given Adsflt on AdNull intravenously and, after 15 days, spleens and livers were harvested to quantify tumor burden. Adslft-treated animals had minimal residual splenic tumors and liver metastases; in contrast, control animals had bulky splenic tumors and extensive liver metastases (p < 0.003). Second, mice with preestablished lung metastases showed a significant reduction in pulmonary metastases with regionally administered Adslft (intratracheal, p < 0.02) but not when the vector was systemically administered (intravenous, p > 0.9). Finally, mice with primary subcutaneous tumors treated with intratumoral administration of Adslft showed significant tumor suppression (p < 0.05) not observed in AdNull-treated mice or mice given Adslft intravenously (p > 0.3). We conclude that Ad-mediated in vivo regional delivery of a secreted form of the extracellular domain of the flt-1 VEGF receptor can effectively inhibit regional tumor growth, a strategy that may provide a means to control tumor growth within the treated organ without the risk of systemic antiangiogenesis. It has been known that vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of cancer by inducing angiogenesis. The present study is designed to evaluate the hypothesis that regional anti-VEGF therapy, and hence regional control of tumor growth, can be achieved by adenovirus (Ad)-mediated regional transfer of the cDNA that encodes a secreted form of the extracellular domain of the human flt-1 VEGF receptor (Adsflt). Using subcutaneous, liver metastatic, and lung metastatic models of tumor growth, the data demonstrate that the regional delivery of the sflt cDNA via an Ad vector dramatically inhibits the growth of preestablished tumors in animal models, but only within the organs to which the vector is administered, i.e., the Adsflt vector functions in a regional fashion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Dimerization of cell surface receptors in signal transduction
Heldin, C.-H. (1995) · Cell · doi:10.1016/0092-8674(95)90404-2 · Cited by 1,634
Brown, L. F., Yeo, K. T., Berse, B., Yeo, T. K., Senger, D. R., Dvorak, H. F., & van de Water, L. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.5.1375 · Cited by 878
Shweiki, D., Neeman, M., Itin, A., & Keshet, E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.768 · Cited by 599
Cited by
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Molecular and biological properties of vascular endothelial growth factor
Ferrara, N. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900019 · Cited by 1,158
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004
Mäkinen, T., Jussila, L., Veikkola, T., Karpanen, T., Kettunen, M. I., Pulkkanen, K. J., Kauppinen, R., Jackson, D. G., Kubo, H., Nishikawa, S.-I., et al. (2001) · Nature Medicine · doi:10.1038/84651 · Cited by 777
Role of vascular endothelial growth factor in the regulation of angiogenesis
Ferrara, N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00610.x · Cited by 731
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Veikkola, T., Jussila, L., Makinen, T., Karpanen, T., Jeltsch, M., Petrova, T. V., Kubo, H., Thurston, G., McDonald, D. M., Achen, M. G., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1223 · Cited by 663
Kim, S., Bell, K., Mousa, S. A., & Varner, J. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65005-5 · Cited by 635
Structure and Function of VEGF/VEGF-receptor System Involved in Angiogenesis.
Shibuya, M. (2001) · Cell Structure and Function · doi:10.1247/csf.26.25 · Cited by 504
Vasculogenesis and Angiogenesis
Patan, S. (2004) · Cancer Treatment and Research · doi:10.1007/978-1-4419-8871-3_1 · Cited by 430
Vasculogenesis and Angiogenesis as Mechanisms of Vascular Network Formation, Growth and Remodeling
Patan, S. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006493130855 · Cited by 382
Blezinger, P., Wang, J., Gondo, M., Quezada, A., Mehrens, D., French, M., Singhal, A., Sullivan, S., Rolland, A., Ralston, R., et al. (1999) · Nature Biotechnology · doi:10.1038/7895 · Cited by 299
Lung Overexpression of the Vascular Endothelial Growth Factor Gene Induces Pulmonary Edema
Kaner, R. J., Ladetto, J. V., Singh, R., Fukuda, N., Matthay, M. A., & Crystal, R. G. (2000) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.22.6.3779 · Cited by 277
Self-citationKuo, C. J., Farnebo, F., Yu, E. Y., Christofferson, R., Swearingen, R. A., Carter, R., von Recum, H. A., Yuan, J., Kamihara, J., Flynn, E., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081615298 · Cited by 271
Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
Saaristo, A., Karpanen, T., & Alitalo, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203969 · Cited by 264
Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1)
Shibuya, M. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00026-7 · Cited by 260
Wolfert, M. A., Dash, P. R., Nazarova, O., Oupicky, D., Seymour, L. W., Smart, S., Strohalm, J., & Ulbrich, K. (1999) · Bioconjugate Chemistry · doi:10.1021/bc990025r · Cited by 253
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Self-citation
Metadata
- Authors
- Kong, H.-L., Hecht, D., Song, W., Kovesdi, I., Hackett, N. R., Yayon, A., & Crystal, R. G.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1998-04-10
- Volume
- 9
- Issue
- 6
- Pages
- 823-833
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1993301801
- Cited by
- 180
- References
- 7
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.